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Aim: Evaluate early (0–12 weeks) and later (12–24 weeks) treatment outcomes in subjects
with type 2 diabetes not achieving glycaemic control with oral antidiabetes drugs (OADs).
Methods: Selected data were pooled from 15 randomised, controlled treat-to-target (fasting
plasma glucose < 100 mg/dL [<5.6 mmol/L]) trials adding insulin glargine to metformin, a
sulphonylurea, or both. Glycaemic and hypoglycaemia parameters, insulin dose, and body
weight at weeks 12 and 24 were assessed using individualised subject-level data.
Results: Data from 2837 subjects were analysed. HbA1c decreased from 8.8% (73 mmol/mol)
at baseline by 1.4% (15 mmol/mol) at Week 12, and a further 0.2% (2 mmol/mol) at Week 24 in
the pooled population. Similar reductions were observed across the different treatment
groups. HbA1c < 7.0% (<53 mmol/mol) was reached by 34.8% of participants at Week 12 and
an additional 24.3% by Week 24. Hypoglycaemia incidence and rates were similar during the
early and continued treatment periods across all treatment combinations, but were
markedly lower for insulin glargine plus metformin versus the other 2 regimens.
Conclusions: Early and sustained glycaemic benefits with a low-risk of hypoglycaemia are
observed after initiation of insulin glargine in a pooled type 2 diabetes cohort previously
uncontrolled on OADs.
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A recent joint position statement issued by the American
Diabetes Association (ADA) and the European Association for
the Study of Diabetes (EASD) recommends initiating addition-
al therapy for persons with type 2 diabetes mellitus (T2DM)
unable to achieve glycaemic control through lifestyle changes
in conjunction with metformin [1]. If glycated haemoglobin
(HbA1c) targets are not achieved within 3 months, it is
suggested that therapy should be further advanced with the
addition of a second oral antidiabetes drug (OAD) or a basal
insulin. In some cases, triple therapy is utilised.
Adding a basal insulin to therapy for persons with T2DM
who have failed to achieve adequate glycaemic control with an
OAD as monotherapy or in combinations has been widely
shown to improve glycaemic control [2–5]. Achieving near
normoglycaemia may prevent or delay the onset and
progression of diabetes-related complications, especially if
complemented by a reduction in cholesterol and hypertension
[4,6–9].
A recent analysis of studies involving the addition of basal
insulin glargine to OADs in persons with uncontrolled T2DM,
found that the greatest glycaemic benefits, including reduc-
tions in HbA1c and achievement of glycaemic goals, occurred
in those who were in receipt of metformin-only prior to the
initiation of basal insulin therapy [5]. Weight gain and
incidence of hypoglycaemia were also lowest in those
receiving metformin-only prior to insulin initiation, despite
the higher dose of basal insulin when added to metformin
therapy [5]. These data provide strong support for the
introduction of basal insulin as second-line therapy to
metformin.
The goal of basal insulin therapy is to improve fasting blood
glucose control and subsequently daytime blood glucose
control, while limiting the risk of hypoglycaemia both during
and after insulin dose titration. This objective has been
facilitated with the introduction of the basal insulin analogues
insulin glargine and insulin detemir, and, more recently,
insulin degludec all of which have overcome some of the
limitations associated with both neutral protamine Hagedorn
(NPH) insulin and Lente insulin (discontinued). Both NPH and
Lente insulin demonstrated considerable variability in ab-
sorption from the subcutaneous tissue with pronounced
peaks in their time–action profile [10], which increases the
risk of nocturnal hypoglycaemia when administered before
the evening meal or bedtime [11,12]. Many healthcare
providers remain reluctant to initiate basal insulin analogue
preparations for their patients. Fear of hypoglycaemia, related
costs, and the need for more frequent self-monitoring of blood
glucose are all perceived as important barriers for both
persons with T2DM and healthcare providers [13–16].
The current study was designed to evaluate glycaemic
control and the occurrence of hypoglycaemia in randomised
controlled trials (RCTs) after the initiation and titration of
insulin glargine, in persons with T2DM who were previously
inadequately controlled with a variety of OAD therapy
regimens. This analysis is based on the pooling of standar-
dised outcomes in the treatment arms from 15 individual
RCTs. This study is further to a previous and separate analysisconducted using the same dataset [17]. This was to assess
overall efficacy and safety outcomes in subjects adding insulin
glargine to metformin, a sulphonylurea, or metformin plus a
sulphonylurea, and receiving that drug combination for a 24-
week treatment period. The aim was to explore the early (0–12
weeks) and later (12–24 weeks) glycaemic control, and
corresponding incidences and event rates of hypoglycaemia
in a systematic way following the introduction of insulin
glargine.
2. Methods
2.1. Study selection and population
Eligible studies had to be prospective RCTs conducted in
accordance with Good Clinical Practice guidelines, and had to
have individual participant-level data available for both
efficacy and safety outcomes. A total of 15 prospective, phase
IIIb and phase IV RCTs conducted by Sanofi and predecessor
companies between 2000 and 2012 were considered for
inclusion. In these trials, insulin glargine was initiated in
insulin-naı¨ve subjects whose T2DM was not controlled by
previous OAD therapy.
Following initiation of insulin glargine (generally at a daily
dose of 10 U or 0.2 U/kg at bedtime), insulin adjustments were
made using a treat-to-target algorithm to achieve a fasting
plasma glucose (FPG) target of 100 mg/dL (5.6 mmol/L). For
inclusion, the duration of the studies had to be 24 weeks.
Subject-level data were obtained from each trial. Subjects
included were adults with T2DM treated during the active
insulin study periods with either insulin glargine plus
metformin; insulin glargine plus a sulphonylurea; or insulin
glargine plus metformin and a sulphonylurea combined. The
analysis did not include those from the control arms.
2.2. Outcomes
Glycaemic control was evaluated by determining the mean
HbA1c and FPG at initiation of insulin glargine (baseline) and
subsequently at treatment weeks 12 and 24. Mean change
from baseline in HbA1c and FPG, and percentage of subjects
achieving the HbA1c target of <7.0% (<53 mmol/mol) and FPG
target  100 mg/dL (5.6 mmol/L), i.e. treatment responders,
were determined at weeks 12 and 24. Insulin dose and body
weight were evaluated at initiation of insulin glargine, and at
weeks 12 and 24.
The incidences of hypoglycaemia and event rates were
calculated for the periods 0–12 weeks (also referred to as
titration period) and 12–24 weeks (maintenance period).
Overall hypoglycaemic events were defined as those with
confirmed plasma glucose < 70 mg/dL (<3.9 mmol/L) or
<56 mg/dL (<3.1 mmol/L); or requiring third-party assistance.
Nocturnal hypoglycaemic events were defined as those with
confirmed plasma glucose < 70 mg/dL or <56 mg/dL, occur-
ring between 00:01 and 05:59. Severe hypoglycaemic events
were defined using two definitions: those events requiring
third-party assistance; or those events requiring third-party
assistance in addition to confirmed plasma glucose < 36 mg/
dL (<2.0 mmol/L).
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Analyses of data for each of the three insulin glargine/OAD
treatment regimens, and for the 3 treatment combinations
pooled together, were conducted for baseline characteristics
and for efficacy and hypoglycaemia outcomes. Each individual
study was also evaluated for mean HbA1c and FPG data at
baseline and at weeks 12 and 24, and for hypoglycaemia
incidences (i.e., the percentage of participants with 1
hypoglycaemic event) and annualised event rates (episodes
per patient year) for the periods 0–12 and 12–24 weeks.
Changes in mean HbA1c and FPG from baseline to Week 12,
and from Week 12 to Week 24, as well as HbA1c and FPG data
and responder rates (achievement of HbA1c < 7.0% [<53 mmol/
mol] and also <7.5% [<58 mmol/mol], and FPG  100 mg/dL
[5.6 mmol/L]) at weeks 12 and 24 were analysed.
Hypoglycaemic events recorded up to and including Week
12 were used for the 0–12-week analyses. Events occurring
through 1 day after the end of the treatment period (last dose
or Week 24) were included in the 12–24-week analyses.
The adjusted incidences and event rates of hypoglycaemia
were derived from a general linear model, which included
baseline body mass index (BMI), duration of diabetes, age,
treatment combination, study, and interaction of duration and
treatment combination as factors for overall hypoglycaemia.
Baseline BMI, duration of diabetes, age, treatment combination,
and study were included as factors for nocturnal hypoglycae-
mia, and baseline BMI, duration of diabetes, age, and treatment
combination as factors for severe hypoglycaemia.
3. Results
3.1. Studies and participants
A total of 15 RCTs were evaluated encompassing 2837
participants with T2DM meeting the inclusion criteria (Sup-
plementary Table 1) [4,18–31]. A total of 634 participants from 5
studies were treated with insulin glargine plus metformin; 906
participants from 6 studies received insulin glargine plus a
sulphonylurea; and 1297 participants from 9 studies were
treated with insulin glargine plus metformin in combination
with a sulphonylurea.
Overall, the participants had a mean age of 57.7 years, 46.2%
were women, the mean BMI was 30.6 kg/m2, and the mean
known duration of T2DM was 9.0 years (Table 1). Study
participants treated with insulin glargine plus metformin were
younger, had a shorter known duration of T2DM compared with
those receiving insulin glargine plus a sulphonylurea or insulin
glargine plus metformin in combination with a sulphonylurea.
Those treated with insulin glargine plus a sulphonylurea had a
lower weight and BMI at baseline and a higher HbA1c and FPG
level at baseline compared with those receiving insulin glargine
plus metformin or insulin glargine plus metformin in combi-
nation with a sulphonylurea (Table 1).
3.2. Glycaemic control
Glycaemic control improved following the initiation of insulin
glargine and subsequent titration, with HbA1c and FPG
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all 3 treatment combinations. In each study these reductions
were maintained or further improved at Week 24 (Fig. 1;
Supplementary Tables 2–4).
In the pooled population, mean HbA1c decreased by 1.4%
(15 mmol/mol) at Week 12 (from 8.8% [73 mmol/mol] at
baseline) and by 1.6% (18 mmol/mol) at Week 24, a further
0.2% reduction (2 mmol/mol). The magnitudes of the mean
HbA1c reductions at Week 12 and Week 24 were similar for
insulin glargine plus metformin, insulin glargine plus a
sulphonylurea, and insulin glargine plus metformin and a
sulphonylurea, with reductions of 1.4% (15 mmol/mol), 1.3%
(14 mmol/mol), and 1.4% (15 mmol/mol), respectively, at Week
12; and additional reductions of 0.3% (3 mmol/mol), 0.1%
(1 mmol/mol), and 0.2% (2.2 mmol/mol), respectively, at Week
24. In the pooled population, the HbA1c target < 7.0%
(<53 mmol/mol) was reached at Week 12 by 34.8% of
participants (Fig. 2). Of those participants who had anFig. 1 – HbA1c (a) and fasting plasma glucose (FPG) (b) outcomes
with insulin glargine according to background oral antidiabetes
whisker plot description: lower whisker represents the minimu
midline of box represents median value; x represents mean va
whisker represents the maximum value.)HbA1c  7.0% at Week 12, the HbA1c target was achieved by
24.3% at Week 24.
The proportion of study participants who achieved the
HbA1c target < 7.0% was greatest for those treated with
insulin glargine plus metformin, followed by insulin glargine
plus metformin and a sulphonylurea, and then insulin
glargine plus a sulphonylurea, at weeks 12 and 24, and
cumulatively (Fig. 2). Corresponding results for participants
who achieved HbA1c < 7.5% (<58 mmol/mol) are illustrated in
Fig. 2.
In the pooled population, mean FPG had decreased by
74.0 mg/dL (4.1 mmol/L) at Week 12, with only a small further
decrease of 3.2 mg/dL (0.2 mmol/L) at Week 24 (Fig. 1). The
magnitude of the mean FPG reduction from baseline to Week
12 was greatest with insulin glargine plus a sulphonylurea
(82.0 mg/dL [4.6 mmol/L]), followed by insulin glargine plus
metformin and a sulphonylurea (70.3 mg/dL [3.9 mmol/L]),
and finally insulin glargine plus metformin (68.0 mg/dL at baseline, Week 12, and Week 24 in participants treated
 drug treatment and in the pooled population. (Box and
m value; bottom of lower box rests on the first quartile;
lue; top of upper box represents the third quartile; upper
Fig. 2 – Proportion of participants achieving the treatment targets of HbA1c < 7.0% (<53 mmol/mol) and <7.5% (<58 mmol/mol)
between baseline and Week 12, Week 12 and Week 24, and from baseline to Week 24 (overall). aCategory of participants
achieving HbA1c < 7.0%/<7.5% was limited to those with an HbA1c I 7.0%/I7.5% at baseline. bCategory of participants
achieving HbA1c < 7.0%/<7.5% was limited to those with an HbA1c I 7.0%/I7.5% at Week 12. cCategory of participants
achieving HbA1c < 7.0%/<7.5% overall (baseline to Week 24) was limited to those with an HbA1c I 7.0%/I7.5% at baseline.
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of further reduction in FPG was greatest with insulin glargine
plus metformin (6.1 mg/dL [0.3 mmol/L]), followed by
insulin glargine plus metformin and a sulphonylurea
(3.4 mg/dL [0.2 mmol/L]), and then insulin glargine plus a
sulphonylurea (1.3 mg/dL [0.1 mmol/L]). In the pooled
population, the FPG target (100 mg/dL) was achieved by
31.1% of participants at Week 12 and 25.0% of participants
who were above target at Week 12 had achieved the target by
Week 24. The proportion of study participants who achieved
the FPG target was again greatest for those treated with
insulin glargine plus metformin (36.1% by Week 12; 31.1%
by Week 24). More participants treated with insulin glargine
plus a sulphonylurea achieved the FPG target at weeks 12 and
24 than those treated with insulin glargine plus metformin
and a sulphonylurea (31.7% and 24.0% vs 28.3% and 23.2%,
respectively).
By Week 12, >80% of the maximum treatment effect (in
terms of reductions in HbA1c) had been achieved compared
with glycaemic control at Week 24 for each concomitant OAD
treatment regimen with insulin glargine (pooled population
87.5%, insulin glargine plus metformin 82.4%, insulin glargine
plus a sulphonylurea 92.9%, and insulin glargine plus metfor-
min and a sulphonylurea 87.5%).
3.3. Insulin glargine dose
Insulin dose profiles by weight over time illustrated a higher
dose-requirement in subjects treated with insulin glargine
plus metformin from approximately Week 3 onwards,
compared with the other 2 treatment regimens (Fig. 3). In
the pooled population, the mean daily dose of insulin glargine
at initiation was 0.16 U/kg (13.3 U; range 0.01–0.84 U/kg),0.40 U/kg at Week 12 (34.9 U; range 0.01–1.36 U/kg), and
0.45 U/kg at Week 24 (40.8 U; range 0.02–1.91 U/kg; Fig. 3 inset).
This represented a change from baseline to Week 12 of 0.24 U/
kg and 0.05 U/kg from Week 12 to Week 24. For the individual
treatment regimens the mean daily doses at initiation of
insulin glargine were: 0.16 U/kg (13.8 U; range 0.02–0.36 U/kg)
for insulin glargine plus metformin; 0.20 U/kg (15.8 U; range
0.01–0.84 U/kg) for insulin glargine plus a sulphonylurea; and
0.13 U/kg (11.2 U; range 0.01–0.44 U/kg) for insulin glargine
plus metformin and a sulphonylurea (Fig. 3 inset). In
participants treated with insulin glargine plus metformin,
insulin doses increased at weeks 12 and 24 to 0.45 U/kg (39.9 U;
range 0.05–1.32 U/kg, change from baseline, 0.29 U/kg) and
0.52 U/kg (47.6 U; range 0.05–1.62 U/kg; change from Week 12,
0.06 U/kg), respectively (Fig. 3 inset). In participants treated
with insulin glargine plus sulphonylurea, dose increased to
0.39 U/kg at Week 12 (33.2 U; range 0.02–1.15 U/kg; change
from baseline, 0.19 U/kg) and 0.44 U/kg at Week 24 (38.1 U;
range 0.02–1.68 U/kg; change from Week 12, 0.04 U/kg; Fig. 3
inset). Finally, in participants treated with insulin glargine
plus metformin and a sulphonylurea, dose increased to 0.37 U/
kg at Week 12 (33.7 U; range 0.01–1.36 U/kg; change from
baseline, 0.24 U/kg) and 0.42 U/kg at Week 24 (39.5 U; range
0.02–1.91 U/kg; change from Week 12, 0.05 U/kg; Fig. 3 inset).
3.4. Body weight
In the pooled population, mean weight increased from 86.4 kg
at baseline to 87.6 kg at Week 12 and 88.5 kg at Week 24. Mean
body weight at baseline was 88.0 kg for insulin glargine plus
metformin, 81.8 kg for insulin glargine plus a sulphonylurea,
and 88.9 kg for insulin glargine plus metformin and a
sulphonylurea.
Fig. 3 – Insulin dose profiles by weight (U/kg) over time in participants treated with insulin glargine according to background
oral antidiabetes drug treatment and in the pooled population.
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increase was lowest in participants treated with insulin
glargine plus metformin (0.1 kg and 0.7 kg, respectively),
followed by insulin glargine plus metformin and a sulphonyl-
urea (1.2 kg and 0.8 kg, respectively); it was greatest in
participants treated with insulin glargine plus a sulphonylurea
(1.7 kg and 1.2 kg, respectively).
3.5. Hypoglycaemia
The adjusted incidences and event rates of overall, nocturnal,
and severe hypoglycaemia in the early insulin glargine
treatment period (weeks 0–12) and later treatment period
(weeks 12–24) overall, and by treatment combination are
represented in Table 2 (unadjusted data are presented in
Supplementary Table 5).
For the pooled treatmentgroups, the adjusted incidences and
rates of overall and nocturnal hypoglycaemia for participants
with blood glucose < 70 mg/dL or <56 mg/dL were markedly
lower in those treated with insulin glargine plus metformin
compared with those receiving the other two treatment
combinations (Table 2). The highest rates of overall and
nocturnal hypoglycaemia were observed in participants treated
with insulin glargine plus metformin and a sulphonylurea.Severe hypoglycaemia was rare across all three treatment
combinations.
When comparing the occurrence of hypoglycaemia be-
tween weeks 0–12, and weeks 12–24, the incidences and rates
of hypoglycaemia were essentially similar for both treatment
periods for the individual treatment groups, suggesting no
notable increase in hypoglycaemia between the titration and
subsequent maintenance period of insulin glargine use.
Hypoglycaemia incidences and event rates in the individ-
ual studies are given in Supplementary Table 6.
4. Discussion
In this pooled analyses of selected data from 15 RCTs,
participants with T2DM inadequately controlled on OADs,
achieved early and sustained improvements in glycaemic
control following initiation of insulin glargine using treat-to-
target titration. HbA1c and FPG improvements at weeks 12 and
24 were similar for those treated with insulin glargine plus
metformin, insulin glargine plus a sulphonylurea, and insulin
glargine plus metformin and a sulphonylurea. More than 80%
of the maximum treatment effect, in terms of reductions in
HbA1c, was achieved at 12 weeks of basal insulin therapy. This
Table 2 – Adjusted hypoglycaemia incidence and event rates in the pooled population and by treatment combination.
Insulin
glargine +
metformin
Insulin
glargine +
sulphonylurea
Insulin
glargine +
metformin +
sulphonylurea
Pooled P value
GLA + MET
vs
GLA + SU
P value
GLA + MET
vs
GLA + MET + SU
P value
GLA + SU
vs
GLA + MET + SU
Incidence of hypoglycaemia 0–12 weeks, % participants
Overall
BG < 70 mg/dL 21.80 (2.52) 38.81 (4.66) 39.17 (2.68) 32.65 (1.36) 0.001 <0.001 0.959
BG < 56 mg/dL 8.77 (1.68) 18.57 (4.02) 21.28 (2.46) 15.32 (1.06) 0.19 <0.001 0.659
Nocturnal
BG < 70 mg/dL 6.50 (1.37) 7.01 (2.47) 11.28 (1.86) 8.04 (0.76) 0.871 0.018 0.319
BG < 56 mg/dL 3.07 (1.14) 1.18 (1.02) 6.51 (1.98) 2.90 (0.55) 0.381 0.039 0.122
Severe
Third-party
assistance
1.11 (0.42) 1.48 (0.40) 1.30 (0.32) 1.29 (0.23) 0.534 0.724 0.719
Third-party
assistance and
<36 mg/dL
0.27 (0.21) 0.19 (0.15) 0 0 0.727 <0.001 NE
Event rate of hypoglycaemia 0–12 weeks, episodes/patient-year
Overall
BG < 70 mg/dL 1.72 (0.24) 4.43 (0.86) 5.99 (0.65) 3.57 (0.21) <0.001 <0.001 0.285
BG < 56 mg/dL 0.51 (0.10) 1.41 (0.39) 2.06 (0.31) 1.14 (0.09) 0.007 <0.001 0.340
Nocturnal
BG < 70 mg/dL 0.34 (0.08) 0.46 (0.19) 0.80 (0.16) 0.50 (0.06) 0.576 0.002 0.338
BG < 56 mg/dL 0.16 (0.06) 0.06 (0.06) 0.41 (0.14) 0.16 (0.03) 0.407 0.017 0.109
Severe
Third-party
assistance
0.059 (0.029) 0.109 (0.038) 0.102 (0.031) 0.087 (0.019) 0.305 0.359 0.884
Third-party
assistance and
<36 mg/dLa
0.012 (0.009) 0.009 (0.007) 0 0 0.765 0.963 0.964
Incidence of hypoglycaemia 12–24 weeks, % participants
Overall
BG < 70 mg/dL 27.03 (2.81) 35.91 (4.53) 33.63 (2.56) 32.06 (1.38) 0.089 0.108 0.728
BG < 56 mg/dL 10.71 (1.85) 18.13 (3.93) 22.14 (2.56) 16.40 (1.11) 0.071 <0.001 0.519
Nocturnal
BG < 70 mg/dL 7.77 (1.56) 8.77 (2.79) 11.10 (1.77) 9.12 (0.83) 0.766 0.150 0.596
BG < 56 mg/dL 3.23 (0.97) 4.29 (2.11) 6.53 (1.56) 4.50 (0.62) 0.658 0.038 0.536
Severe
Third-party
assistance
1.26 (0.46) 1.04 (0.35) 0.94 (0.27) 1.07 (0.21) 0.703 0.521 0.809
Third-party
assistance and
<36 mg/dL
0.15 (0.15) 0.09 (0.10) 0.08 (0.08) 0.10 (0.07) 0.754 0.651 0.892
Event rate of hypoglycaemia 12–24 weeks, episodes/patient-year
Overall
BG < 70 mg/dL 2.31 (0.34) 5.42 (1.10) 5.35 (0.62) 4.06 (0.26) <0.001 <0.001 0.963
BG < 56 mg/dL 0.75 (0.15) 1.60 (0.43) 2.13 (0.32) 1.38 (0.11) 0.026 <0.001 0.466
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weeks across the 3 OAD treatment groups assessed. According
to the estimation of the A1C-Derived Average Glucose (ADAG)
study [32], the reductions in FPG observed in our analysis
should have corresponded to a greater improvement in HbA1c
across all treatment groups. We hypothesise that an explana-
tion for this could be that insulin glargine has a specific effect
on pre-breakfast glucose values, thus reducing FPG levels to a
greater degree than the improvement in HbA1c would predict.
This is interesting when considering the dawn phenomenon,
in which a night-to-morning elevation of blood glucose is
observed in patients with diabetes. The potential effect of
insulin glargine on pre-breakfast glucose levels observed in
this analysis supports previous studies demonstrating that
basal insulin regimens abolish the dawn phenomenon by
restraining hepatic glucose production and lipolysis [33].
Responder rates differed across treatment groups; 40.5% of
those treated with insulin glargine plus metformin, 24.6% with
insulin glargine plus a sulphonylurea, and 39.3% with insulin
glargine plus metformin and a sulphonylurea achieved a
HbA1c < 7.0% (<53 mmol/mol) after 12 weeks. Of those
participants who had an HbA1c  7.0% at Week 12, the HbA1c
target was achieved by a further 35.4%, 15.9%, and 26.4%,
respectively, at Week 24. In those treated with insulin glargine
plus metformin, the proportion of participants reaching the
FPG target (100 mg/dL [5.6 mmol/L]) was greater at 12 and
24 weeks, compared with the two other treatment regimens.
Participants treated with insulin glargine plus metformin
had a baseline HbA1c of 8.7% and a T2DM duration of 7.3 years,
compared with baseline HbA1c levels of 9.0% and 8.7% and a
T2DM duration of 9.5 years for both those treated with insulin
glargine plus a sulphonylurea and insulin glargine plus
metformin and a sulphonylurea, respectively. Despite higher
insulin doses (Week 24: 0.53 U/kg for insulin glargine plus
metformin, 0.44 U/kg for insulin glargine plus a sulphonyl-
urea, and 0.42 U/kg for insulin glargine plus metformin and a
sulphonylurea), weight gain among those treated with insulin
glargine plus metformin was lower than that observed with
the regimens containing a sulphonylurea. Taken together, the
results observed here advocate the benefit of adding insulin
glargine to metformin early in the evolution of T2DM, in
support of previous data [5].
In general, adjusted hypoglycaemia incidences were low
during weeks 0–12, i.e. the early titration period (32.65% and
15.32% for overall hypoglycaemia with blood glucose < 70 mg/
dL [<3.9 mmol/L] and <56 mg/dL [<3.1 mmol/L], respectively).
The low risk of hypoglycaemia with insulin glargine was
sustained during the maintenance treatment period (12–24
weeks) with incidences of 32.06% and 16.40%, respectively.
Despite the use of higher insulin doses with insulin glargine
plus metformin, overall hypoglycaemia with blood gluco-
se < 70 mg/dL and < 56 mg/dL was less frequent during both
the titration and maintenance phases of treatment, compared
with either insulin glargine plus a sulphonylurea or insulin
glargine plus metformin and a sulphonylurea (for blood
glucose < 70 mg/dL: 21.80% vs 38.81% and 39.17%, respective-
ly, during weeks 0–12; and 27.03% vs 35.91% and 33.63%,
respectively, during weeks 12–24). A similar pattern was seen
for nocturnal hypoglycaemia (blood glucose < 70 mg/dL and
<56 mg/dL). There was, however, no difference in the
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combinations. This lower rate of hypoglycaemia in partici-
pants treated with insulin glargine plus metformin may have
permitted continued titration of insulin to higher doses and
thus improved HbA1c and FPG target achievement compared
with the regimens including a sulphonylurea.
The incidences of overall hypoglycaemia observed in these
trials were lower than, or comparable to, those reported earlier
in trials of NPH insulin and insulin detemir [3,34,35]. In a 26-
week study comparing the addition of twice-daily insulin
detemir or NPH insulin to current OAD regimens in insulin-
naı¨ve persons with T2DM, the incidence of minor hypo-
glycaemia (defined as self-managed, with a blood gluco-
se < 3.0 mmol/L [<54 mg/dL]) was 41% for insulin detemir and
64% for NPH insulin [34].
In our pooled subject-level analysis, the incidence of
hypoglycaemia was also lower than that observed in a 24-
week treat-to-target (5.0–7.2 mmol/L) trial comparing insulin
detemir and insulin lispro protamine suspension, both
administered once daily at bedtime (with an option to add a
second dose if certain criteria were met), in insulin-naı¨ve
persons with T2DM receiving OADs [35]. Hypoglycaemia was
defined as any time a subject felt they were experiencing
hypoglycaemia or had a blood glucose < 3.9 mmol/L (<70 mg/
dL) even if it was not associated with signs, symptoms, or
treatment. The hypoglycaemia incidence rates were 65.2% for
insulin detemir and 68.9% for insulin lispro protamine
suspension. When limited to only those subjects who were
dosed once-daily (excluding those who met the criteria for
addition of a second injection), incidences of hypoglycaemia
were 71.3% for insulin detemir and 65.2% for insulin lispro
protamine suspension [35].
The key strengths of the present analysis are the inclusion
of nearly 2400 study participants treated with insulin glargine
from 15 RCTs. Pooling of the data from these studies increases
the statistical power of the analysis, resulting in a more
precise estimate of therapeutic benefit (efficacy) and safety for
the 3 regimens that were investigated. Applying established
criteria through standardisation of the endpoints to reduce
study-specific differences is another attribute. The analysis
was, however, limited by the difference in sample size for the 3
treatment regimens assessed; in particular a much smaller
number of participants were treated with insulin glargine plus
metformin. In addition, there were also differences between
the groups that should not be ignored – shorter duration of
T2DM in those treated with insulin glargine plus metformin,
and lower weight at baseline in those treated with insulin
glargine plus a sulphonylurea. It is not known if the results
apply to basal insulin preparations other than insulin glargine.
In addition, outcomes were only assessed up to 24 weeks
following the introduction of insulin glargine treatment.
These findings need to be substantiated in appropriately
designed RCTs. Finally, as the trials included in this analysis
spanned a time period up to 2007, the assessment of the
combination of newer oral and parenteral agents with insulin
glargine was not possible. Nevertheless, the principle of
intensifying treatment to subjects with T2DM by adding basal
insulin when the current oral therapy does not achieve the
desired glycaemic control is in line with the current ADA and
EASD guidelines [1]. The results obtained in this post hocanalysis support the principle of introducing a basal insulin
early when OADs fail to achieve the individually defined
glycaemic control target. The introduction of a basal insulin
can achieve, with adequate titration, an early (by 12 weeks)
and satisfactory response in the majority of subjects (>80% of
the maximum treatment effect in terms of reductions in
HbA1c, 34.8% and 54.4% of participants reaching HbA1c < 7.0
and <7.5%, respectively), with a low risk of hypoglycaemia and
weight gain. Better clinical outcomes were seen in subjects
where insulin glargine was added to metformin only, in whom
the duration of T2DM was shorter, and both hypoglycaemic
event rates and weight gain were lower. Despite equivalent
glycaemic improvement, the risk of hypoglycaemia was
enhanced with the use of a sulphonylurea.
In summary, basal insulin initiation with insulin glargine
using treat-to-target titration among insulin-naı¨ve persons
with T2DM inadequately controlled with OADs, results in
improved early glycaemic control and a low incidence of
hypoglycaemic events and minimal changes in weight. The
majority of the benefits are achieved early, within the first 3
months after insulin initiation, and are maintained and
slightly improved at 6 months. In agreement with previous
findings, the efficacy and safety benefits are most prominent
when adding insulin glargine to a metformin-only regimen
early in the evolution of type 2 diabetes.
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